147 related articles for article (PubMed ID: 20871594)
1. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls.
Mehra KK; Chang MC; Folkins AK; Raho CJ; Lima JF; Yuan L; Mehrad M; Tworoger SS; Crum CP; Saleemuddin A
Mod Pathol; 2011 Jan; 24(1):152-6. PubMed ID: 20871594
[TBL] [Abstract][Full Text] [Related]
2. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.
Shaw PA; Rouzbahman M; Pizer ES; Pintilie M; Begley H
Mod Pathol; 2009 Sep; 22(9):1133-8. PubMed ID: 19543244
[TBL] [Abstract][Full Text] [Related]
3. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
5. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
Cass I; Walts AE; Barbuto D; Lester J; Karlan B
Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
[TBL] [Abstract][Full Text] [Related]
6. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.
Folkins AK; Jarboe EA; Saleemuddin A; Lee Y; Callahan MJ; Drapkin R; Garber JE; Muto MG; Tworoger S; Crum CP
Gynecol Oncol; 2008 May; 109(2):168-73. PubMed ID: 18342932
[TBL] [Abstract][Full Text] [Related]
7. Serous carcinogenesis in the fallopian tube: a descriptive classification.
Jarboe E; Folkins A; Nucci MR; Kindelberger D; Drapkin R; Miron A; Lee Y; Crum CP
Int J Gynecol Pathol; 2008 Jan; 27(1):1-9. PubMed ID: 18156967
[TBL] [Abstract][Full Text] [Related]
8. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.
Saleemuddin A; Folkins AK; Garrett L; Garber J; Muto MG; Crum CP; Tworoger S
Gynecol Oncol; 2008 Nov; 111(2):226-32. PubMed ID: 18718648
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
[TBL] [Abstract][Full Text] [Related]
11. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
Chen EY; Mehra K; Mehrad M; Ning G; Miron A; Mutter GL; Monte N; Quade BJ; McKeon FD; Yassin Y; Xian W; Crum CP
J Pathol; 2010 Sep; 222(1):110-6. PubMed ID: 20597068
[TBL] [Abstract][Full Text] [Related]
12. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
Sakurada S; Watanabe Y; Tokunaga H; Takahashi F; Yamada H; Takehara K; Yaegashi N
Jpn J Clin Oncol; 2018 Sep; 48(9):794-798. PubMed ID: 29982601
[TBL] [Abstract][Full Text] [Related]
15. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
17. [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria].
Lax S
Pathologe; 2009 Dec; 30 Suppl 2():210-6. PubMed ID: 19859709
[TBL] [Abstract][Full Text] [Related]
18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
20. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
